Clinical trials
Lung Cancer (Suspected or Confirmed) clinical trials
Below are recruiting lung cancer (suspected or confirmed) clinical trials, each written for real people, not researchers. We’re tracking 6,632 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05191680RecruitingPhase 2
Testing apalutamide in early prostate cancer active surveillance
This Phase 2 trial tests whether apalutamide can help people with early prostate cancer who choose active surveillance. It uses MRI and biopsy results to confirm the cancer type and location, then checks if treatment is safe and potentially helpful.
Cambridge, CambridgeshireAges 18 years+ - NCT05204108Recruiting
Ultrasound test to check bladder cancer muscle spread
This trial studies a special ultrasound scan with contrast dye to see whether bladder cancer has grown into the muscle layer. It may help doctors plan the best treatment before surgery.
Guangzhou, GuangdongAges 18–75 - NCT05211557RecruitingPhase 1/Phase 2
CAR-T therapy for recurrent ovarian cancer with B7H3
This Phase 1/2 study tests a personalized immune-cell treatment (fully human B7H3 CAR-T) for ovarian cancer that has come back or did not respond. It aims to see whether CAR-T can attack tumors that carry a target called B7H3.
Xuzhou, JiangsuAges 18–70 - NCT05212454RecruitingPhase 3
Capecitabine added after surgery for high-risk ER-positive breast cancer
This Phase 3 study tests whether adding capecitabine (a chemotherapy pill) after breast cancer surgery can lower the chance the cancer comes back. It targets people with hormone-receptor–positive and HER2-negative breast cancer who are considered “high risk.”
Hanzhou, ZhejiangAges 18–70 - NCT05222971RecruitingPhase 2
Olaparib, with or without immunotherapy, for DNA-repair biliary cancer
This Phase 2 study tests olaparib (a targeted anti-cancer pill) alone or with durvalumab (an immunotherapy) for biliary tract cancers that have specific DNA repair gene changes. It’s for people whose cancer has continued after standard platinum chemotherapy, aiming to slow or control the disease.
SeoulAges 19 years+ - NCT05223803RecruitingPhase 2
Study radiation for early metastatic prostate cancer
This Phase 2 trial tests a radiation-focused approach for people with newly diagnosed (de novo) prostate cancer that has spread to a small number of spots, especially in bone. It aims to see how well the treatment controls the cancer while keeping side effects manageable.
La Jolla, CaliforniaAges 18 years+ - NCT05228431RecruitingPhase 2
Tested treatment plan for locally advanced rectal cancer
This Phase 2 study looks at a modified “sandwich” treatment sequence for people with locally advanced rectal cancer—aiming to control the cancer before and after surgery. It may help you if you’re eligible and can follow the study’s treatment and safety requirements.
Guangzhou, GuangdongAges 18–75 - NCT05231122RecruitingPhase 2
Pembrolizumab and bevacizumab for recurrent ovarian cancer
This trial studies whether adding pembrolizumab to bevacizumab (and sometimes an anti-CD40 drug) can help control recurrent ovarian, fallopian tube, or primary peritoneal cancer. It also looks at whether the treatment can shrink tumors and keep them from growing for longer.
Buffalo, New YorkAges 18 years+ - NCT05232409RecruitingPhase 1
Zeaxanthin in metastatic cancer, alone or with pembrolizumab
This Phase 1 study tests whether zeaxanthin is safe and what dose to use in people with metastatic cancer. It also studies zeaxanthin together with pembrolizumab (an immunotherapy) to see if the combination is tolerable after cancer has progressed despite PD-1/PD-L1 treatment.
Paramus, New JerseyAges 18–99 - NCT05239624RecruitingPhase 2
Enfortumab plus pembrolizumab for muscle-invasive bladder cancer
This Phase 2 study tests how well two anti-cancer medicines—enfortumab vedotin and pembrolizumab—work for people with muscle-invasive bladder cancer that has spread to nearby lymph nodes (but not distant organs). It may help shrink the cancer and improve treatment outcomes before or around planning major surgery.
Miami, FloridaAges 18 years+ - NCT05250648RecruitingPhase 4
HIPEC with mitomycin C after surgery for colon cancer in the belly
This study looks at adding a heated medicine treatment (HIPEC with mitomycin C) during surgery to treat colon cancer that has spread to the lining of the abdomen (peritoneum). It aims to improve outcomes after surgeons remove visible tumor completely.
Elche, AlicanteAges 18 years+ - NCT05255003RecruitingPhase 4
Anticoagulation options for low platelets with cancer blood clots
This trial studies how best to prevent and treat dangerous blood clots in people with cancer who also have very low platelets. It may help guide safer blood-thinner treatment when bleeding risk is high.
Edmonton, AlbertaAges 18 years+ - NCT05255653RecruitingPhase 2/Phase 3
Personalized after-surgery treatment for endometrial cancer by tumor type
This trial studies which after-surgery (adjuvant) treatment works best when endometrial cancer is classified by specific tumor DNA/molecular features. You may be offered treatment based on the tumor results, aiming to improve outcomes and lower the risk of the cancer coming back.
TorontoAges 18 years+ - NCT05267912Recruiting
Using tumor organoids to guide treatment for advanced cancers
This study tests whether growing a patient's tumor cells in a dish (called an organoid) can help doctors choose the best next treatment. It is for people with advanced colorectal or pancreatic cancer who have run out of standard options.
Bordeaux, FranceAges 18 years+ - NCT05270213RecruitingPhase 1
RBS2418 for advanced cancers after standard treatments
This early-phase study tests RBS2418 in people with advanced, metastatic solid tumors that have not responded to standard treatment. It aims to see if the drug can shrink tumors or help control disease, and to learn what doses are safest.
Scottsdale, ArizonaAges 18 years+ - NCT05292742RecruitingPhase 2
Continue targeted breast cancer therapy or switch to a new combo
This Phase 2 study compares two treatment plans after breast surgery when cancer did not fully disappear before surgery. It tests whether adding trastuzumab, pyrotinib, and capecitabine works better than continuing the original targeted therapy.
Fuzhou, FujianAges 18–75 - NCT05297617RecruitingPhase 2
Shorter hormone therapy for low-risk postmenopausal breast cancer
This Phase 2 trial studies whether women with very low-risk, hormone-receptor positive breast cancer can safely take hormone therapy for a shorter time. It may help reduce side effects if shorter treatment works as well as the longer standard plan.
LimogesAges 51 years+ - NCT05299840Recruiting
Test a device to choose the first chemo for metastatic colon cancer
This study tests whether using the Oncogramme® device to guide the first-line treatment improves care for people with metastatic colorectal (colon/rectum) cancer. If the device helps pick the most suitable standard chemotherapy plan, it could lead to better outcomes than choosing without it.
MarseilleAges 18 years+ - NCT05304858Recruiting
Study of prostate cancer spread using biopsy and lab tests
This trial studies the “microenvironment” around prostate cancer metastases, using specimens taken during biopsy and other scans. It may help researchers understand what drives prostate cancer spread and improve future treatment choices.
New York, New YorkAges 18 years+ - NCT05305131RecruitingPhase 2
Testing chemotherapy with or without extra cancer medicines for nasopharyngeal cancer
This Phase 2 study compares standard chemotherapy (gemcitabine plus cisplatin) against the same chemotherapy plus pembrolizumab and bevacizumab. It aims to see which combination works better for EBV-positive nasopharyngeal cancer before any prior treatment.
SingaporeAges 1.8 years–99 years - NCT05318469RecruitingPhase 1/Phase 2
Ivermectin with immunotherapy for metastatic triple-negative breast cancer
This trial studies whether ivermectin, given together with immunotherapy (balstilimab or pembrolizumab), can help treat metastatic triple-negative breast cancer. It mainly looks at safety first, and may also explore how well the treatment works for people whose cancer has spread.
Los Angeles, CaliforniaAges 18 years+ - NCT05319639RecruitingPhase 1/Phase 2
Irinotecan plus immunotherapy for stomach cancer
This Phase I/II trial tests how well irinotecan combined with tislelizumab (an immunotherapy) treats advanced stomach or gastroesophageal junction adenocarcinoma. It mainly looks at safety and the best way to use this combination, and may help shrink tumors or slow disease growth.
Fuzhou, FujianAges 18–75 - NCT05324332Recruiting
Two scans to study prostate cancer in the same group
This trial looks at prostate cancer patients who have not started treatment yet and have two different PET/CT scans close together. It may help doctors compare how these scans show prostate cancer in the body.
Beijing, Beijing MunicipalityAges 18–90 - NCT05325632RecruitingPhase 2
HER2 breast cancer vaccine plus chemo and targeted antibodies
This Phase 2 study tests a personalized immune-therapy vaccine made from your immune cells, given with weekly paclitaxel and HER2-targeted antibodies (trastuzumab and pertuzumab). It aims to improve treatment outcomes for people with HER2-positive breast cancer before standard local treatment (like surgery and radiation).
Tampa, FloridaAges 18 years+
Hear when a new Lung Cancer (Suspected or Confirmed) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer (suspected or confirmed)?
- Yes. Clin2 currently lists 6,632 recruiting lung cancer (suspected or confirmed) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer (suspected or confirmed) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer (suspected or confirmed) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.